Save

A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

PHASE3RECRUITING

Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery with a balloon (angioplasty) and a small mesh tube (stent) although life saving can cause this clot to break up and get washed downstream, which can make the heart attack worse. The investigators can measure the amount of damage caused to the microcirculation by calculating the IMR (Index of Microcirculatory resistance).

This can be measured by a wire in the coronary artery with a pressure sensor at the tip. If the IMR is elevated, it is suggestive of extensive microcirculatory damage. A clot dissolving medicine can be administered in the artery to try and reduce the IMR which can reduce damage to the heart muscle and improve outcomes.

Impaired microcirculatory perfusion in patients as a result of ST-elevation myocardial infarction (STEMI) is associated with poor clinical outcomes. This project seeks to identify patients with impaired microcirculatory perfusion after STEMI and to assess whether acute improvement in microcirculatory perfusion in these patients by the use of intracoronary thrombolytic therapy results in improved clinical outcomes.

Simpliy with AI

Study details:

Patients presenting to the participating hospitals with a heart attack will be approached to participate in the study. After angioplasty has been performed, the IMR will be measured in the infarct related artery. If the IMR is \>32 patients will be randomised to receive intracoronary clot dissolving therapy in the form of low dose tenecteplase (TNK) or water as a placebo.

Patients who have an IMR ≤32 will be followed up in a registry. Cardiac enzymes will be measured at baseline and discharge. Randomised participants will receive a cardiac MRI at discharge (3-7 days post primary PCI) and at 6 months post PCI.

All participants will be followed up at 30 days, and 6, 12 and 24 months following discharge.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Adult men and women aged over 18 who present with STEMI within 6 hours of symptom onset. Patients will be eligible if they have symptoms consistent with myocardial ischaemia (chest pain, dyspnoea) for at least 20 minutes accompanied by definite ECGs indicating STEMI as defined by Australian National Heart Foundation (NHF) guidelines

Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances

Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study

(At time of PCI) Patient has received metallic drug-eluting stent

Participant consents to have a 3-7 day (discharge) and 6 month follow up cardiac MRI

Exclusion criteria

Previous coronary bypass grafting

Other residual lesions with ≥50% diameter stenosis in the culprit vessel

Prior myocardial infarction in the target territory

Presence of contraindications to thrombolytic therapy (including history of stroke and recent brain surgery active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension)

Presence of contraindications to adenosine infusion for IMR measurement including sinus node disease, moderate to severe bronchoconstrictive disease and second or third-degree atrioventricular (AV) block

Diagnosis of metastatic disease

Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety

Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol

Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.

Participation in any investigational study in the previous 30 days

(Cardiac MRI cohort only) Presence of contraindications to contrast enhanced MRI including severe claustrophobia, pregnancy, pacemakers, non-MRI compatible aneurysm clips, defibrillators and estimated glomerular filtration rate of <30mL/min.

(At time of PCI) Patients who received GpIIb/IIIa treatment prior to IMR measurement

Patients who do not undergo primary PCI due to lack of severity of culprit lesion or other reasons.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2021-10-14

Primary completion: 2024-12-31

Study completion finish: 2026-12-31

Study type

OTHER

Phase

PHASE3

Trial ID

NCT03998319

Intervention or treatment

DRUG: Tenecteplase (1/3 systemic weight based dose)

OTHER: Sterile water for injection (WFI)

Conditions

• STEMI
• Elevated IMR (>32)

Condition: STEMI, Elevated IMR (>32)
DRUG: Tenecteplase (1/3 systemic weight based dose) and other drugs
Camperdown, New South Wales, Australia and more
Sponsor: University of Sydney

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Royal Prince Alfred Hospital

Research sites nearby

Select from list below to view details:

Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Tenecteplase (1/3 systemic weight based dose) Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.	DRUG: Tenecteplase (1/3 systemic weight based dose) 50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
PLACEBO_COMPARATOR: Sterile Water for injection (WFI) Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.	OTHER: Sterile water for injection (WFI) Placebo comparative arm.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
To compare the number of participants who experience cardiovascular mortality and rehospitalisation for heart failure at 24 months in those given tenecteplase with those given placebo (Cardiac MRI cohort only)	Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review.	24 months
To compare MI size as a % of LV mass and intramyocardial bleeding rates in participants at 6 months post PCI in those given low dose tenecteplase with those given placebo.	MI size and intramyocardial bleeding rates will be assessed upon cardiac MRI at discharge (3-7 days post procedure) as a baseline measure, and at 6 months post-PCI.	6 months after primary PCI procedure.

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Number of participants who experience individual components of the primary endpoint: (a) cardiovascular mortality at 24 months, (b) rehospitalisation for heart failure at 24 months;	Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review, respectively.	24 months after primary PCI procedure
Number of Major Adverse Cardiac Events (MACE)	Major Adverse Coronary Events (these are combination events involving cardiovascular death, non-fatal MI, non-fatal stroke and unstable angina) assessed from physical assessment and medical record review	24 months after primary PCI procedure
All-cause mortality	All-cause mortality assessed by physical assessment and medical record review.	24 months after primary PCI procedure
Number of stroke events	Stroke events will be assessed by medical record review. Assessment will cover all aspects of the stroke event (including type, severity, frequency).	24 months after primary PCI procedure
Number of incidences of bailout treatment use for no-reflow syndrome	Use of Bailout treatment for no-reflow syndrome assessed by medical record review	24 months after primary PCI procedure
Occurrence of major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium	Major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium. Assessed by medical record review.	24 months after primary PCI procedure
Index of Microcirculatory Resistance (IMR)	Index of microcirculatory resistance (IMR) measurement assessed by coronary pressure wire data output review. This is a simple unit scale, with a higher number indicating a worse outcome with a score of more than 25 indicating abnormal microcirculatory function in the heart.	0-2 hours
Fractional Flow Reserve (FFR)	Fractional Flow Reserve measurement assessed by coronary pressure wire data output review prior to randomisation and immediately after primary PCI	0-2 hours
Coronary Flow Reserve (CFR)	Coronary Flow Reserve measurement assessed by coronary pressure wire data output review, prior to randomisation and immediately after primary PCI.	0-2 hours
Wall Motion Score	The score is measured by simple unit scale (1 = normal, 2 = hypokinetic (muscle impaired), 3= akinetic (muscle dead)). Each of the 16 segments of the hearts is scored, with the total being divided by 16 to derive the score.	0-6 months
Left ventricular ejection fraction (LVEF)	Left ventricular ejection fraction measurement from echocardiogram will be used to assess cardiac function prior to randomisation, 48 hours and 6 months post primary PCI	0-6 months
Myocardial Blush Grade	Myocardial Blush Grade measurement from angiogram will be used to assess cardiac function. The score goes from 0 to 3, with 3 being normal and 0 being absence of myocardial blush	0-2 hours
TIMI Myocardial Perfusion Grade	Thrombolysis in myocardial infarction score from angiogram will be used to assess myocardial perfusion. This score goes from 0 to 3, 3 indicates normal flow within the artery and 0 indicates a complete coronary occlusion.	0-2 hours
TIMI corrected frame count	Thrombolysis in myocardial infarction score with corrected frame count from angiogram to assess myocardial perfusion	0-2 hours
Cardiac enzyme measurements	Cardiac enzyme levels including troponin T, creatine kinase, creatine kinase-MB and high sensitivity troponin T, from blood samples collected during the hospitalisation period (prior to primary PCI and at 8, 16, 24 and 32 hours post primary PCI).	0-32 hours

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.